News | November 07, 2024
Vijaya Diagnostic Centre posts Q2 FY25 PAT at Rs. 41.95 Cr
Revenue growth was fueled by higher volumes and contributions from both existing and new centres
Revenue growth was fueled by higher volumes and contributions from both existing and new centres
Reinforces position as first commercially approved contract development and manufacturing organization (CDMO) for ADCs in North America
Lupin's R&D teams are working on products with a near-zero global warming potential propellant
Union Government will provide a health cover of Rs. 5 lakh to any elderly person above 70 years of age
VYALEV is the first and only subcutaneous 24-hour continuous infusion of levodopa-based therapy for the treatment of motor fluctuations in advanced Parkinson's disease
HYMPAVZI’s approval is based on Phase 3 study results demonstrating substantial bleed reduction compared to routine prophylaxis
Approval is based on Phase III INAVO120 results, showing the Itovebi (inavolisib)-based regimen more than doubled progression-free survival compared with palbociclib and fulvestrant alone in the first-line setting
To set a new standard in oncology, offering highly targeted radiation therapy that improves treatment precision, and accelerates recovery for cancer patients
The acquisition will strengthen the overall company’s position as leading global CRO services partner
The Lilly Medicine Foundry is set to drive innovation in drug production and make medicines for clinical trials
Subscribe To Our Newsletter & Stay Updated
